186 related articles for article (PubMed ID: 23494361)
1. Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation.
Chinen Y; Kuroda J; Ohshiro M; Shimura Y; Mizutani S; Nagoshi H; Sasaki N; Nakayama R; Kiyota M; Yamamoto-Sugitani M; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
Int J Hematol; 2013 Apr; 97(4):511-9. PubMed ID: 23494361
[TBL] [Abstract][Full Text] [Related]
2. Clinical features and outcomes of 35 disseminated intravascular coagulation cases treated with recombinant human soluble thrombomodulin at a single institution.
Kawano N; Yoshida S; Ono N; Himeji D; Nagahiro Y; Sayaka Kawano ; Yamashita K; Ikeda N; Uezono S; Ochiai H; Kawano F; Kikuchi I; Ishikawa F; Shimoda K; Ueda A; Akashi K
J Clin Exp Hematop; 2011; 51(2):101-7. PubMed ID: 22104308
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Combined Thrombomodulin and Antithrombin in Anticoagulant Therapy for Acute Cholangitis-induced Disseminated Intravascular Coagulation.
Morita N; Nakahara K; Morita R; Suetani K; Michikawa Y; Sato J; Tsuji K; Ikeda H; Matsunaga K; Watanabe T; Matsumoto N; Okuse C; Suzuki M; Itoh F
Intern Med; 2019 Apr; 58(7):907-914. PubMed ID: 30449812
[TBL] [Abstract][Full Text] [Related]
4. Multicenter clinical experience with recombinant soluble thrombomodulin for disseminated intravascular coagulation associated with severe acute cholecystitis.
Ogura T; Eguchi T; Amano M; Sano T; Nishioka N; Miyano A; Tsujimae M; Tanimura H; Yamada T; Terashima Y; Okada A; Higuchi K
Thromb Res; 2019 Apr; 176():74-78. PubMed ID: 30780007
[TBL] [Abstract][Full Text] [Related]
5. Effect of Recombinant Human Soluble Thrombomodulin on Coagulation-Related Variables in Patients With Sepsis-Induced Disseminated Intravascular Coagulation: A Retrospective Observational Study.
Mitaka C; Kawagoe I; Satoh D; Hayashida M
Clin Appl Thromb Hemost; 2021; 27():10760296211050356. PubMed ID: 34859680
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of Recombinant Thrombomodulin for Sepsis-Associated Disseminated Intravascular Coagulation Caused by Urinary Tract Infections].
Tachibana A; Iida K; Itami Y; Hashimura M; Toyoshima Y; Hosokawa Y; Fujimoto K
Hinyokika Kiyo; 2023 Nov; 69(11):309-314. PubMed ID: 38031329
[TBL] [Abstract][Full Text] [Related]
7. Effects of recombinant human soluble thrombomodulin treatment for disseminated intravascular coagulation at a single institution--an analysis of 62 cases caused by infectious diseases and 30 cases caused by hematological diseases.
Kawano N; Tasaki A; Kuriyama T; Tahara Y; Yoshida S; Ono N; Himeji D; Yamashita K; Shibata Y; Goto T; Inoue T; Yokota-Ikeda N; Uezono S; Yuge A; Nishiguchi T; Kinjo T; Ogura Y; Beppu K; Ueda Y; Kinoshita M; Moritake H; Shimoda K; Ochiai H; Ueda A
Intern Med; 2014; 53(3):205-13. PubMed ID: 24492688
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of disseminated intravascular coagulation by recombinant human soluble thrombomodulin in patients with acute myeloid leukemia.
Ookura M; Hosono N; Tasaki T; Oiwa K; Fujita K; Ito K; Lee S; Matsuda Y; Morita M; Tai K; Negoro E; Kishi S; Iwasaki H; Ueda T; Yamauchi T
Medicine (Baltimore); 2018 Nov; 97(44):e12981. PubMed ID: 30383650
[TBL] [Abstract][Full Text] [Related]
9. Correlation between plasma activity of ADAMTS-13 and coagulopathy, and prognosis in disseminated intravascular coagulation.
Hyun J; Kim HK; Kim JE; Lim MG; Jung JS; Park S; Cho HI
Thromb Res; 2009 May; 124(1):75-9. PubMed ID: 19162307
[TBL] [Abstract][Full Text] [Related]
10. ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin.
Ohshiro M; Kuroda J; Kobayashi Y; Akaogi T; Kawata E; Uoshima N; Kamitsuji Y; Kaneko H; Shimura K; Shimazaki C; Murakami S; Hatsuse M; Okano A; Kobayashi T; Uchiyama H; Matsumoto Y; Horiike S; Taniwaki M
Am J Hematol; 2012 Jan; 87(1):116-9. PubMed ID: 21989545
[No Abstract] [Full Text] [Related]
11. Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study.
Akahoshi T; Sugimori H; Kaku N; Tokuda K; Nagata T; Noda E; Morita M; Hashizume M; Maehara Y
Eur J Trauma Emerg Surg; 2015 Oct; 41(5):531-8. PubMed ID: 26038004
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy of early use of recombinant soluble thrombomodulin for disseminated intravascular coagulation complicated with hematologic malignancies].
Usami M; Kuroda H; Yoshida M; Sakamoto H; Shimoyama S; Kanari Y; Yamada M; Abe T; Fujii S; Maeda M
Rinsho Ketsueki; 2015 Jun; 56(6):673-80. PubMed ID: 26256878
[TBL] [Abstract][Full Text] [Related]
13. Thrombomodulin in the management of acute cholangitis-induced disseminated intravascular coagulation.
Suetani K; Okuse C; Nakahara K; Michikawa Y; Noguchi Y; Suzuki M; Morita R; Sato N; Kato M; Itoh F
World J Gastroenterol; 2015 Jan; 21(2):533-40. PubMed ID: 25593469
[TBL] [Abstract][Full Text] [Related]
14. Clinical Impact of Recombinant Soluble Thrombomodulin for Disseminated Intravascular Coagulation Associated with Severe Acute Cholangitis.
Okuda A; Ogura T; Imanishi M; Miyano A; Nishioka N; Higuchi K
Gut Liver; 2018 Jul; 12(4):471-477. PubMed ID: 29699063
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of recombinant human soluble thrombomodulin in severe postpartum hemorrhage with disseminated intravascular coagulation.
Sugawara J; Suenaga K; Hoshiai T; Sato T; Nishigori H; Nagase S; Yaegashi N
Clin Appl Thromb Hemost; 2013 Sep; 19(5):557-61. PubMed ID: 22496090
[TBL] [Abstract][Full Text] [Related]
16. Impact of Recombinant Human Soluble Thrombomodulin for Disseminated Intravascular Coagulation.
Itoh S; Shirabe K; Kohnoe S; Sadanaga N; Kajiyama K; Yamagata M; Anai H; Harimoto N; Ikegami T; Yoshizumi T; Maehara Y
Anticancer Res; 2016 May; 36(5):2493-6. PubMed ID: 27127163
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors.
Ouchi K; Takahashi S; Chikamatsu S; Ito S; Takahashi Y; Kawai S; Okita A; Kasahara Y; Okada Y; Imai H; Komine K; Saijo K; Takahashi M; Shirota H; Takahashi M; Gamoh M; Ishioka C
Int J Clin Oncol; 2018 Aug; 23(4):790-798. PubMed ID: 29511940
[TBL] [Abstract][Full Text] [Related]
18. [Successful treatment with recombinant thrombomodulin for disseminated intravascular coagulation complicated with hemophagocytic syndrome].
Yamazaki H; Kondo T; Tatsumi G; Kotani S; Arai Y; Shirakawa K; Kitano T; Hishizawa M; Kadowaki N; Takaori-Kondo A
Rinsho Ketsueki; 2015 Mar; 56(3):312-6. PubMed ID: 25876785
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial.
Saito H; Maruyama I; Shimazaki S; Yamamoto Y; Aikawa N; Ohno R; Hirayama A; Matsuda T; Asakura H; Nakashima M; Aoki N
J Thromb Haemost; 2007 Jan; 5(1):31-41. PubMed ID: 17059423
[TBL] [Abstract][Full Text] [Related]
20. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort.
Matsushita T; Watanabe J; Honda G; Mimuro J; Takahashi H; Tsuji H; Eguchi Y; Kitajima I; Sakata Y
Thromb Res; 2014 May; 133(5):772-81. PubMed ID: 24636871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]